PMC:7195088 / 20922-21126 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"672","span":{"begin":40,"end":48},"obj":"Species"},{"id":"796","span":{"begin":14,"end":24},"obj":"Chemical"},{"id":"937","span":{"begin":61,"end":69},"obj":"Disease"}],"attributes":[{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"Tax:9606"},{"id":"A796","pred":"tao:has_database_id","subj":"796","obj":"MESH:C000606551"},{"id":"A937","pred":"tao:has_database_id","subj":"937","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of remdesivir vs. placebo in patients with severe COVID-19. Double-blind RCT (NCT04257656, recruiting). Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28."}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":173,"end":178},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Comparison of remdesivir vs. placebo in patients with severe COVID-19. Double-blind RCT (NCT04257656, recruiting). Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T102","span":{"begin":61,"end":69},"obj":"Disease"}],"attributes":[{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of remdesivir vs. placebo in patients with severe COVID-19. Double-blind RCT (NCT04257656, recruiting). Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T235","span":{"begin":14,"end":24},"obj":"Chemical"}],"attributes":[{"id":"A235","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Comparison of remdesivir vs. placebo in patients with severe COVID-19. Double-blind RCT (NCT04257656, recruiting). Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T146","span":{"begin":71,"end":114},"obj":"Sentence"},{"id":"T147","span":{"begin":115,"end":204},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of remdesivir vs. placebo in patients with severe COVID-19. Double-blind RCT (NCT04257656, recruiting). Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28."}